Effects of site-specific infusions of methionine sulfoximine on the temporal progression of seizures in a rat model of mesial temporal lobe epilepsy

Highlights • Inhibition of brain glutamine synthetase using methionine sulfoximine (MSO) causes recurrent seizures. • The seizures are most frequent during the first 2–3 days of MSO infusion. • Severe (Racine stage 4–5) seizures become more prevalent after several days. • The site of MSO infusion wi...

Full description

Saved in:
Bibliographic Details
Published in:Epilepsy research 2015-09, Vol.115, p.45-54
Main Authors: Dhaher, Roni, Wang, Helen, Gruenbaum, Shaun E, Tu, Nathan, Lee, Tih-Shih W, Zaveri, Hitten P, Eid, Tore
Format: Article
Language:English
Subjects:
Animals
Astrocytes
Astrocytes - drug effects
Astrocytes - enzymology
Brain - enzymology
Disease Models, Animal
Disease Progression
Electrocorticography
Epilepsy, Temporal Lobe - enzymology
Glutamate
Glutamate-Ammonia Ligase - antagonists & inhibitors
Glutamate-Ammonia Ligase - metabolism
Glutamine synthetase
Infusions, Intraventricular
Infusions, Parenteral
Male
Metabolism
Methionine Sulfoximine - administration & dosage
Neurology
Plasticity
Rats, Sprague-Dawley
Seizures - enzymology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Highlights • Inhibition of brain glutamine synthetase using methionine sulfoximine (MSO) causes recurrent seizures. • The seizures are most frequent during the first 2–3 days of MSO infusion. • Severe (Racine stage 4–5) seizures become more prevalent after several days. • The site of MSO infusion within the brain affects the pattern of seizures.
ISSN:0920-1211
1872-6844
DOI:10.1016/j.eplepsyres.2015.05.005